Novartis receives FDA approval for Rhapsido® , the only oral, targeted BTKi treatment for chronic spontaneous urticaria
QIMC Defines Multiple New Hydrogen Hot Zones in Nova Scotia, Reports Stronger Preliminary DDH-26-05 Hydrogen Readings and Triples 2026 Nova Scotia Exploration Program Across a 43-km District-Scale Corridor
